Key Insights
The Latin American Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor market is poised for significant expansion, projected to reach USD 3.51 billion in 2025 and grow at a robust Compound Annual Growth Rate (CAGR) of 6.3% through 2033. This upward trajectory is primarily fueled by the increasing prevalence of type 2 diabetes across the region, a growing awareness of advanced treatment options, and favorable reimbursement policies in key markets like Brazil and Mexico. The drug segment is dominated by established players such as Invokana (Canagliflozin), Jardiance (Empagliflozin), and Farxiga/Forxiga (Dapagliflozin), which are seeing increased adoption due to their proven efficacy in managing blood glucose levels and reducing cardiovascular and renal complications associated with diabetes. The market’s growth is further supported by investments in healthcare infrastructure and the expanding reach of pharmaceutical companies in emerging Latin American economies.
Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Market Size (In Billion)
The competitive landscape features major pharmaceutical giants including Janssen Pharmaceuticals, Eli Lilly, AstraZeneca, Bristol Myers Squibb, and Boehringer Ingelheim, all actively engaged in market penetration and product development strategies. While the market demonstrates strong growth potential, certain restraints may include the high cost of these advanced therapies, which can pose affordability challenges for a segment of the population, and regulatory hurdles in some smaller Latin American countries. However, these challenges are being mitigated by increasing government initiatives to improve diabetes management and the sustained demand for innovative treatments that offer better patient outcomes. The geographical segment breakdown highlights Brazil and Mexico as leading markets, with the rest of Latin America expected to contribute substantially to overall market growth as access and affordability improve.
Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Company Market Share
This in-depth report provides a comprehensive analysis of the Latin American Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitor market, offering critical insights into market dynamics, growth trajectories, and competitive landscapes. The study covers the historical period from 2019 to 2024, with a base year of 2025 and a detailed forecast extending to 2033. The Latin America SGLT-2 inhibitor market is projected to reach an estimated value of $X.X billion in 2025 and grow at a substantial CAGR of Y.Y% during the forecast period. This report is essential for pharmaceutical companies, healthcare providers, investors, and regulatory bodies seeking to understand and capitalize on the evolving SGLT-2 inhibitor market in this dynamic region.
Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Market Concentration & Innovation
The Latin American SGLT-2 inhibitor market is characterized by a moderate to high level of concentration, dominated by a few key global pharmaceutical players. Innovation is a primary driver, with continuous research and development focused on expanding therapeutic indications beyond diabetes, particularly for cardiovascular and renal diseases. Regulatory frameworks across Latin American countries are evolving, with increasing alignment with international standards, facilitating market access for novel SGLT-2 inhibitors. Product substitutes, primarily other classes of antidiabetic drugs, exist, but the unique benefits of SGLT-2 inhibitors in managing comorbidities are driving their adoption. End-user trends indicate a growing awareness and demand for comprehensive disease management solutions, including those addressing cardiovascular and renal health alongside glycemic control. Merger and acquisition (M&A) activities, while not as prevalent as in more mature markets, are expected to play a role in market consolidation and strategic partnerships, with potential deal values in the hundreds of millions of dollars.
- Market Share Concentration: Dominated by key players, with top 3-5 companies holding over XX% of the market share.
- Innovation Drivers: Expansion of indications to HF, CKD; novel drug formulations; combination therapies.
- Regulatory Frameworks: Increasing harmonization with global standards; evolving reimbursement policies.
- Product Substitutes: Other diabetes medications (DPP-4 inhibitors, GLP-1 receptor agonists, insulin); lifestyle modifications.
- End-User Trends: Demand for integrated care; patient preference for less invasive treatments; focus on chronic disease management.
- M&A Activities: Potential for strategic partnerships and acquisitions to enhance market presence and product portfolios.
Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Industry Trends & Insights
The Latin American SGLT-2 inhibitor market is experiencing robust growth driven by a confluence of factors, including the rising prevalence of type 2 diabetes and associated cardiovascular and renal comorbidities, increasing healthcare expenditure, and growing physician and patient awareness of the benefits of SGLT-2 inhibitors. Technological advancements in drug delivery and formulation are enhancing patient compliance and efficacy. Consumer preferences are shifting towards treatments that offer broader health benefits beyond glycemic control, making SGLT-2 inhibitors with their cardioprotective and renoprotective properties highly attractive. The competitive landscape is characterized by intense competition among major pharmaceutical companies, with ongoing efforts to secure market share through strategic marketing, clinical trial data dissemination, and expanded access programs. The market penetration of SGLT-2 inhibitors, while growing, still has significant room for expansion across various patient demographics and healthcare settings within Latin America. The estimated CAGR for the Latin America SGLT-2 inhibitor market is projected to be around Y.Y% during the forecast period of 2025–2033, reflecting strong underlying demand and market expansion potential. The total market size is expected to grow from approximately $X.X billion in 2025 to over $Z.Z billion by 2033.
Dominant Markets & Segments in Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America
Brazil and Mexico are poised to be the dominant markets within the Latin American SGLT-2 inhibitor landscape. Brazil, with its large population, high prevalence of diabetes, and increasing healthcare infrastructure investment, represents a significant market opportunity. Mexico follows closely, driven by a similar disease burden and a growing adoption of advanced therapies. The rest of Latin America, encompassing countries like Argentina, Colombia, and Chile, presents emerging but substantial growth potential as healthcare systems mature and access to innovative medicines expands.
Dominant Drug Segments:
- Jardiance (Empagliflozin): Expected to hold a significant market share due to its established efficacy and broad indication portfolio, including heart failure and chronic kidney disease. Its strong clinical trial data supporting cardiovascular and renal benefits will continue to drive its adoption.
- Farxiga/Forxiga (Dapagliflozin): Another major player, benefiting from expanding indications and robust clinical evidence. Its approval for heart failure across the full spectrum of ejection fraction and its potential in chronic kidney disease management will fuel its market dominance.
- Invokana (Canagliflozin): Will continue to be a key player, especially with its established efficacy in diabetes management and its demonstrated benefits in reducing cardiovascular events and slowing kidney disease progression.
- Suglat (Ipragliflozin): While a significant contributor, it may hold a comparatively smaller market share than the leading brands in this region, though its unique profile and potential for specific patient populations will ensure its relevance.
Key Drivers for Dominance in Brazil and Mexico:
- High Diabetes Prevalence: Both countries have a substantial and growing diabetic population, creating a large addressable market for SGLT-2 inhibitors.
- Increasing Healthcare Expenditure: Rising government and private healthcare spending facilitates greater access to advanced pharmaceutical treatments.
- Growing Awareness of Comorbidities: Increased understanding of the link between diabetes and cardiovascular/renal diseases is driving the demand for drugs with pleiotropic effects.
- Favorable Regulatory Environments: While evolving, regulatory bodies in Brazil and Mexico are increasingly approving innovative therapies, accelerating market entry.
- Robust Pharmaceutical Distribution Networks: Well-established pharmaceutical supply chains ensure broader accessibility of SGLT-2 inhibitors across these nations.
Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Product Developments
Product developments in the Latin American SGLT-2 inhibitor market are centered on expanding the therapeutic utility of existing molecules and optimizing drug delivery. Companies are actively pursuing label expansions for their SGLT-2 inhibitors to include indications beyond type 2 diabetes, such as heart failure (HF) and chronic kidney disease (CKD). These advancements leverage the cardioprotective and renoprotective properties of SGLT-2 inhibitors, addressing significant unmet medical needs. Competitive advantages are being built on robust clinical evidence demonstrating reduced risk of cardiovascular events, hospitalizations for heart failure, and progression of kidney disease. Innovations in fixed-dose combination therapies are also emerging, aiming to improve patient adherence and simplify treatment regimens.
Report Scope & Segmentation Analysis
This report segments the Latin American SGLT-2 inhibitor market based on Drug Type and Geography.
The Drug Type segmentation includes:
- Invokana (Canagliflozin): This segment will see sustained growth driven by its established role in diabetes management and proven cardiovascular and renal benefits.
- Jardiance (Empagliflozin): Projected for significant expansion due to its broad indications, including heart failure and chronic kidney disease, supported by extensive clinical data.
- Farxiga/Forxiga (Dapagliflozin): Expected to be a leading segment, driven by recent approvals for heart failure across all ejection fractions and strong evidence for CKD.
- Suglat (Ipragliflozin): This segment will contribute to the market, catering to specific patient needs and geographical preferences.
The Geography segmentation includes:
- Brazil: Anticipated to be the largest market, characterized by a high prevalence of diabetes and growing healthcare infrastructure.
- Mexico: Poised for substantial growth, driven by a large patient population and increasing adoption of advanced therapies.
- Rest of Latin America: Encompasses emerging markets like Argentina, Colombia, and Chile, offering significant untapped potential and future growth opportunities.
Key Drivers of Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Growth
The growth of the SGLT-2 inhibitor market in Latin America is propelled by several key drivers. The escalating prevalence of type 2 diabetes and its associated cardiovascular and renal comorbidities creates a substantial and growing patient pool requiring effective treatment options. Increasing healthcare expenditure across the region translates to greater accessibility and affordability of innovative pharmaceuticals. Furthermore, a growing physician and patient awareness of the pleiotropic benefits of SGLT-2 inhibitors, including their cardioprotective and renoprotective effects, is driving their prescription and uptake. Favorable regulatory pathways for new drug approvals and expanded indications also play a crucial role in market expansion.
Challenges in the Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Sector
Despite the promising growth, the SGLT-2 inhibitor market in Latin America faces several challenges. High drug costs compared to older antidiabetic medications can limit accessibility for a significant portion of the population, particularly in regions with lower per capita income. Reimbursement policies vary across countries and can be complex, affecting market penetration. Limited awareness and understanding among some healthcare providers and patients regarding the full spectrum of benefits beyond glycemic control can hinder optimal utilization. Furthermore, supply chain disruptions and logistical challenges in some parts of the region can impact product availability.
Emerging Opportunities in Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America
Emerging opportunities in the Latin American SGLT-2 inhibitor market are abundant. The expansion of indications to include heart failure and chronic kidney disease opens up substantial new patient populations. Growing investment in real-world evidence generation tailored to Latin American demographics will further solidify the value proposition of SGLT-2 inhibitors. The development of fixed-dose combination therapies offers improved patient adherence and convenience, presenting a significant market advantage. Furthermore, the increasing focus on preventive healthcare and chronic disease management by governments and payers provides a fertile ground for the widespread adoption of SGLT-2 inhibitors as foundational therapies.
Leading Players in the Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Market
- Janssen Pharmaceuticals
- Eli Lilly
- AstraZeneca
- Bristol Myers Squibb
- Boehringer Ingelheim
- Astellas
- 1 Other Key Players
Key Developments in Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Industry
- February 2023: AstraZeneca's Forxiga (dapagliflozin) has been approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction, including HF with mildly reduced and preserved ejection fraction.
- April 2022: Nippon Boehringer Ingelheim's SGLT-2 inhibitor Jardiance (empagliflozin) obtained a label update from PMDA in Japan, allowing its use in patients with chronic heart failure with preserved ejection fraction (HFpEF) in addition to those with heart failure with reduced ejection fraction (HFrEF).
Strategic Outlook for Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Market
The strategic outlook for the SGLT-2 inhibitor market in Latin America is highly positive, driven by expanding therapeutic frontiers and increasing demand for comprehensive chronic disease management. Key growth catalysts include the robust clinical evidence supporting cardiovascular and renal benefits, which are crucial given the high burden of these comorbidities in the region. Pharmaceutical companies will focus on strategic market penetration through enhanced patient access programs, targeted physician education initiatives, and collaborations with local healthcare authorities. The continued exploration of novel indications and the development of innovative drug formulations will further solidify the market's growth trajectory, presenting significant opportunities for stakeholders to contribute to improved patient outcomes and capture substantial market share. The market is expected to witness continued innovation and expansion, making it a crucial area for investment and strategic planning within the global pharmaceutical landscape.
Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Segmentation
-
1. Drug
- 1.1. Invokana (Canagliflozin)
- 1.2. Jardiance (Empagliflozin)
- 1.3. Farxiga/Forxiga (Dapagliflozin)
- 1.4. Suglat (Ipragliflozin)
-
2. Geography
- 2.1. Brazil
- 2.2. Mexico
- 2.3. Rest of latin America
Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Segmentation By Geography
- 1. Brazil
- 2. Mexico
- 3. Rest of latin America
Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Regional Market Share
Geographic Coverage of Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America
Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 6.3% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Prevalence of Genitourinary Disorders; Increasing Number of Pipeline Products
- 3.3. Market Restrains
- 3.3.1. Lack of Therapy Compliance; Increasing Advent of Counterfeit Drugs
- 3.4. Market Trends
- 3.4.1. Rising Diabetes Prevalence in Latin America Region
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Drug
- 5.1.1. Invokana (Canagliflozin)
- 5.1.2. Jardiance (Empagliflozin)
- 5.1.3. Farxiga/Forxiga (Dapagliflozin)
- 5.1.4. Suglat (Ipragliflozin)
- 5.2. Market Analysis, Insights and Forecast - by Geography
- 5.2.1. Brazil
- 5.2.2. Mexico
- 5.2.3. Rest of latin America
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. Brazil
- 5.3.2. Mexico
- 5.3.3. Rest of latin America
- 5.1. Market Analysis, Insights and Forecast - by Drug
- 6. Brazil Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Drug
- 6.1.1. Invokana (Canagliflozin)
- 6.1.2. Jardiance (Empagliflozin)
- 6.1.3. Farxiga/Forxiga (Dapagliflozin)
- 6.1.4. Suglat (Ipragliflozin)
- 6.2. Market Analysis, Insights and Forecast - by Geography
- 6.2.1. Brazil
- 6.2.2. Mexico
- 6.2.3. Rest of latin America
- 6.1. Market Analysis, Insights and Forecast - by Drug
- 7. Mexico Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Drug
- 7.1.1. Invokana (Canagliflozin)
- 7.1.2. Jardiance (Empagliflozin)
- 7.1.3. Farxiga/Forxiga (Dapagliflozin)
- 7.1.4. Suglat (Ipragliflozin)
- 7.2. Market Analysis, Insights and Forecast - by Geography
- 7.2.1. Brazil
- 7.2.2. Mexico
- 7.2.3. Rest of latin America
- 7.1. Market Analysis, Insights and Forecast - by Drug
- 8. Rest of latin America Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Drug
- 8.1.1. Invokana (Canagliflozin)
- 8.1.2. Jardiance (Empagliflozin)
- 8.1.3. Farxiga/Forxiga (Dapagliflozin)
- 8.1.4. Suglat (Ipragliflozin)
- 8.2. Market Analysis, Insights and Forecast - by Geography
- 8.2.1. Brazil
- 8.2.2. Mexico
- 8.2.3. Rest of latin America
- 8.1. Market Analysis, Insights and Forecast - by Drug
- 9. Competitive Analysis
- 9.1. Market Share Analysis 2025
- 9.2. Company Profiles
- 9.2.1 Janssen Pharmaceuticals
- 9.2.1.1. Overview
- 9.2.1.2. Products
- 9.2.1.3. SWOT Analysis
- 9.2.1.4. Recent Developments
- 9.2.1.5. Financials (Based on Availability)
- 9.2.2 Eli Lilly
- 9.2.2.1. Overview
- 9.2.2.2. Products
- 9.2.2.3. SWOT Analysis
- 9.2.2.4. Recent Developments
- 9.2.2.5. Financials (Based on Availability)
- 9.2.3 AstraZeneca
- 9.2.3.1. Overview
- 9.2.3.2. Products
- 9.2.3.3. SWOT Analysis
- 9.2.3.4. Recent Developments
- 9.2.3.5. Financials (Based on Availability)
- 9.2.4 Bristol Myers Squibb
- 9.2.4.1. Overview
- 9.2.4.2. Products
- 9.2.4.3. SWOT Analysis
- 9.2.4.4. Recent Developments
- 9.2.4.5. Financials (Based on Availability)
- 9.2.5 Boehringer Ingelheim
- 9.2.5.1. Overview
- 9.2.5.2. Products
- 9.2.5.3. SWOT Analysis
- 9.2.5.4. Recent Developments
- 9.2.5.5. Financials (Based on Availability)
- 9.2.6 1 Other Key Players
- 9.2.6.1. Overview
- 9.2.6.2. Products
- 9.2.6.3. SWOT Analysis
- 9.2.6.4. Recent Developments
- 9.2.6.5. Financials (Based on Availability)
- 9.2.7 Astellas
- 9.2.7.1. Overview
- 9.2.7.2. Products
- 9.2.7.3. SWOT Analysis
- 9.2.7.4. Recent Developments
- 9.2.7.5. Financials (Based on Availability)
- 9.2.1 Janssen Pharmaceuticals
List of Figures
- Figure 1: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue Breakdown (undefined, %) by Product 2025 & 2033
- Figure 2: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Share (%) by Company 2025
List of Tables
- Table 1: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Drug 2020 & 2033
- Table 2: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Geography 2020 & 2033
- Table 3: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Region 2020 & 2033
- Table 4: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Drug 2020 & 2033
- Table 5: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Geography 2020 & 2033
- Table 6: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Country 2020 & 2033
- Table 7: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Drug 2020 & 2033
- Table 8: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Geography 2020 & 2033
- Table 9: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Country 2020 & 2033
- Table 10: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Drug 2020 & 2033
- Table 11: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Geography 2020 & 2033
- Table 12: Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America Revenue undefined Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America?
The projected CAGR is approximately 6.3%.
2. Which companies are prominent players in the Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America?
Key companies in the market include Janssen Pharmaceuticals, Eli Lilly, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, 1 Other Key Players, Astellas.
3. What are the main segments of the Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America?
The market segments include Drug, Geography.
4. Can you provide details about the market size?
The market size is estimated to be USD XXX N/A as of 2022.
5. What are some drivers contributing to market growth?
Increasing Prevalence of Genitourinary Disorders; Increasing Number of Pipeline Products.
6. What are the notable trends driving market growth?
Rising Diabetes Prevalence in Latin America Region.
7. Are there any restraints impacting market growth?
Lack of Therapy Compliance; Increasing Advent of Counterfeit Drugs.
8. Can you provide examples of recent developments in the market?
February 2023: AstraZeneca's Forxiga (dapagliflozin) has been approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction, including HF with mildly reduced and preserved ejection fraction.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in N/A.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America?
To stay informed about further developments, trends, and reports in the Sodium-Glucose Cotransport-2 Inhibitor Market in Latin America, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
